Athira Pharma’s tumultuous journey to phase 2/3 Alzheimer’s disease data has ended in failure. The trial found fosgonimeton was no better than placebo on the primary and key secondary endpoints, driving investors to cut the cord holding up the biotech’s stock price.
After raising $170 million back in February, metabolic disease-focused BioAge Labs has filed to debut on the public market.
Arsenal Biosciences is moving on up. The cell therapy company has added on $325 million in ammunition with big-name backers like Regeneron joining the artillery as the biotech sets out to build the biggest—and best—house on the block.
Eli Lilly’s hunt for obesity targets has led it to the dark genome. The Big Pharma has put together a deal worth up to $1 billion in biobucks to partner with Haya Therapeutics to find multiple regulatory-genome-derived RNA-based drug targets.
Aelis Farma’s hopes of securing a quick, positive decision on a $100 million option payment have gone up in smoke. The French biotech reported the failure of its phase 2b cannabis use disorder (CUD) study Wednesday, prompting its partner Indivior to say it doesn’t currently expect to exercise its option.
Shares of Planet Labs on Monday dropped after the company provided a guidance for the fourth quarter that missed analysts expectations following weaker-than-expected third-quarter results.
Gold prices moved higher on Monday, on track to settle at their highest in just over two weeks after touching an intraday high of $2,700 an ounce.
A slide for market superstar Nvidia helped pull U.S. stock indexes down from their records
Shares of HealthEquity dropped after the company’s outlook for the next fiscal year missed Wall Street expectations.
Embecta has secured an FDA clearance for its first wearable insulin delivery system, with a patch pump designed for people with either Type 1 or Type 2 diabetes.
Jazz HER2 bispecific posts 59% survival at 30 months in gastric cancer
Pfizer sees weight gain in cancer patients, aims to enter phase 3 in 2025
‘Cooking with gas’: Regeneron sees its Opdualag rival as next big thing for treating solid tumors
IO Biotech’s vaccine and Keytruda combo hits primary endpoint in phase 2 squamous cell carcinoma trial
iTeos-GSK’s TIGIT combo shows 30% more tumor shrinkage than Jemperli, but safety signals scare investors
Eli Lilly sells Life Sciences Studio lab to Arctoris, moving automation platform from San Diego to Oxford
Biolexis enters oral GLP-1 horse race with preclinical study showing small molecule reduced weight of obese mice
AstraZeneca steps out from Daiichi’s shadow, posting data on ADC rivals to AbbVie, Pfizer
Wall Street Rises to Turn a Dismal Week Into Just a Bad One
Tesla Recalling Almost 700,000 Vehicles Due to Tire Pressure Monitoring System Issue
